Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer	Advanced Breast Cancer	Recruiting	Phase 2	2025-11-18		NCT07180160

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Wenjin Yin	8

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Renji Hospital, School of Medicine, Shanghai Jiaotong University	Shanghai	China	18

Clinical trials